Establishment Labs Holdings Inc. $ESTA Shares Sold by Redmile Group LLC

Redmile Group LLC reduced its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 8.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 103,464 shares of the company’s stock after selling 9,200 shares during the quarter. Establishment Labs comprises approximately 0.4% of Redmile Group LLC’s investment portfolio, making the stock its 27th largest position. Redmile Group LLC’s holdings in Establishment Labs were worth $5,875,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Simplify Asset Management Inc. grew its stake in Establishment Labs by 92.1% during the 4th quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock valued at $5,313,000 after acquiring an additional 34,946 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Establishment Labs by 134.3% during the 1st quarter. SG Americas Securities LLC now owns 37,928 shares of the company’s stock worth $2,154,000 after purchasing an additional 21,742 shares during the last quarter. Sigma Planning Corp boosted its holdings in shares of Establishment Labs by 325.5% during the 1st quarter. Sigma Planning Corp now owns 20,424 shares of the company’s stock worth $1,160,000 after purchasing an additional 15,624 shares during the last quarter. AlTi Global Inc. purchased a new stake in shares of Establishment Labs in the first quarter valued at approximately $842,000. Finally, Cannon Global Investment Management LLC purchased a new stake in shares of Establishment Labs in the first quarter valued at approximately $738,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Trading Down 0.2%

Shares of Establishment Labs stock opened at $91.90 on Wednesday. The stock has a 50 day moving average of $83.63 and a 200 day moving average of $73.08. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96. The firm has a market capitalization of $2.70 billion, a price-to-earnings ratio of -61.68 and a beta of 1.06. Establishment Labs Holdings Inc. has a fifty-two week low of $33.35 and a fifty-two week high of $96.99.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. During the same quarter in the prior year, the firm earned ($0.70) EPS. Establishment Labs’s revenue for the quarter was up 44.7% compared to the same quarter last year. As a group, research analysts predict that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Insider Transactions at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director directly owned 927,504 shares in the company, valued at approximately $69,952,351.68. The trade was a 10.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 180,000 shares of company stock valued at $13,225,275. 9.99% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Mizuho boosted their price objective on Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Citigroup lifted their price target on Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. Finally, BTIG Research restated a “buy” rating on shares of Establishment Labs in a research report on Monday, July 13th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and an average price target of $90.43.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.